Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study

Asthma remission- what is it and how can it be achieved?

(2022) Dennis Thomas et al.   EUROPEAN RESPIRATORY JOURNAL

Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study

(2022) Takanori Numata et al.   Journal of Asthma and Allergy

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma

(2022) Ana Gómez-Bastero Fernández et al.   Journal of Asthma and Allergy

Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma

(2021) Grainne d'Ancona et al.   ALLERGY

The relationship between FeNO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma

(2021) A.P. Hearn et al.   Journal of Allergy and Clinical Immunology-In Practice

Sputum mast cell/basophil gene expression relates to inflammatory and clinical features of severe asthma

(2021) Natasha A. Winter et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media

(2021) Satoshi Hamada et al.   ALLERGOLOGY INTERNATIONAL

Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to Five Years

(2021) Stephanie Korn et al.   Journal of Allergy and Clinical Immunology-In Practice

Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study

(2021) Takanori Numata et al.   Journal of Asthma and Allergy

A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumab

(2021) Jonathan Corren et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

(2021) Andrew Menzies-Gow et al.   Lancet Respiratory Medicine

Cycling biologic therapy for severe asthma

(2021) S. Hamada et al.   Pulmonology

Universal Masking in Hospitals in the Covid-19 Era

(2020) Michael Klompas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Benralizumab strongly reduces blood basophils in severe eosinophilic asthma

(2020) Marek Lommatzsch et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study

(2020) Takanori Numata et al.   BMC Pulmonary Medicine

Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

(2020) Joanne E. Kavanagh et al.   CHEST

Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis

(2020) Diego Bagnasco et al.   RESPIRATORY MEDICINE

Japanese guidelines for adult asthma 2020

(2020) Yoichi Nakamura et al.   ALLERGOLOGY INTERNATIONAL

Trends in Hospitalizations for Asthma During the COVID-19 Outbreak in Japan

(2020) Kazuhiro Abe et al.   Journal of Allergy and Clinical Immunology-In Practice

Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy

(2020) Carlo Mümmler et al.   Journal of Allergy and Clinical Immunology-In Practice

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

(2019) Takanori Numata et al.   BMC Pulmonary Medicine

An expert consensus framework for asthma remission as a treatment goal

(2019) Andrew Menzies-Gow et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

(2018) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

(2018) Mario Castro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

(2018) J Mark FitzGerald et al.   Lancet Respiratory Medicine

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

(2018) Sumita Khatri et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Airway innate lymphoid cells in the induction and regulation of allergy

(2018) Taylor A. Doherty et al.   ALLERGOLOGY INTERNATIONAL

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

(2017) Geoffrey L Chupp et al.   Lancet Respiratory Medicine

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study

(2016) Njira Lugogo et al.   CLINICAL THERAPEUTICS

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis

(2016) Christoph S N Klose et al.   NATURE IMMUNOLOGY

Persistently high exhaled nitric oxide and loss of lung function in controlled asthma

(2016) Kazuto Matsunaga et al.   ALLERGOLOGY INTERNATIONAL

The prevalence of severe refractory asthma

(2015) Pieter-Paul W. Hekking et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

(2015) Mario Castro et al.   Lancet Respiratory Medicine

Basophil-Derived Interleukin-4 Controls the Function of Natural Helper Cells, a Member of ILC2s, in Lung Inflammation

(2014) Yasutaka Motomura et al.   IMMUNITY

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

CD203c expression on human basophils is associated with asthma exacerbation

(2010) Emiko Ono et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The minimally important difference of the Asthma Control Test

(2009) Michael Schatz et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY